WIB-National: Executive Women In Bio Breakfast at BIO Digital – Leading During a Pandemic (Webinar)
Tell a Friend About This EventTell a Friend
WIB-National: Executive Women In Bio Breakfast at BIO Digital – Leading During a Pandemic (Webinar)

*- Please note this webinar is at 9:30 a.m. PDT/12:30 p.m. EDT

6/8/2020
When: Monday, June 8, 2020
9:30 a.m. - 10:30 a.m. PDT
Where: Zoom (Online)
Contact: WIB-National


Online registration is closed.
« Go to Upcoming Event List  



Join us virtually at BIO for a WIB-National Webinar on "Leading during the Pandemic" facilitated by Shehnaaz Suliman (EWIB co-chair) with panelists Jung Choi, Natalie Holles, and Elena Ridloff.

Note: This event is open to the general public. It takes place at 9:30 a.m. PDT/12:30 p.m. EDT

Disclaimer: This event may be recorded. If so, there is a possibility your image and or voice may be a part of that recording. If you do not wish for your image to be included please turn off your camera.


Speaker Biographies

Shehnaaz Suliman, M.D., M.B.A., M.Phil., EWIB co-chair. President & COO, Alector. Shehnaaz is a physician and strategy and business development leader with a more than 20 years delivering results in business development, corporate and commercial strategy and early development. She currently serves on the boards of Ultragenyx and 10X Genomics. Previous roles include leadership positions at Gilead, Genentech, Roche and Theravance Biopharma. Her healthcare career began in South Africa and in the UK as a practicing physician. She received her medical degree at the University of Cape Town followed by an MBA, with distinction, and a master’s in development studies from Oxford University, where she was a Rhodes Scholar. Shehnaaz was selected as one of 2017 Fierce Women in Life Sciences.

 

Jung E. Choi, Chief Business & Strategy Officer, Global Blood Therapeutics, Inc.: Jung E. Choi is chief business and strategy officer of Global Blood Therapeutics (NASDAQ: GBT), a publicly-traded biopharmaceutical company focused on creating innovative treatments that provide hope to underserved patient communities including sickle cell disease.  She leads corporate and business development, patient advocacy, government affairs, and program team leadership for a clinical program.  She has over 20 years of executive, transactional, and leadership experience in the biopharmaceutical industry, and has led or managed over 50 transactions exceeding $13 billion in value.  She previously served as senior vice president, corporate development for InterMune during its acquisition and integration into Roche/Genentech, as well as senior vice president, corporate development for Chimerix.  Jung held various management positions of increasing responsibility over nine years at Gilead Sciences, including head of business development, corporate strategy, mergers and acquisitions, and as director of marketing to commercially launch Hepsera, a hepatitis B virus drug.  Prior to Gilead, Jung served as vice president of Bay City Capital, and started her career in strategy consulting at McKinsey & Company as engagement manager.  Jung is a founding leader of the GBT Womens’ Group, and has served on the board of Keys School, a nonprofit K-8 school, as finance committee chair, strategic planning co-chair, and executive committee member.  Jung holds a BA in Human Biology from Stanford University and an MBA from Stanford’s Graduate School of Business. Jung is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network.

 

Natalie Holles has served as President and Chief Executive Officer (CEO) of Audentes since January 2020. She joined the company as Senior Vice President and Chief Operating Officer (COO) in August 2015 and was promoted to President and COO in May 2018. Ms. Holles brings to this role more than twenty years of executive leadership, business development, corporate strategy and commercial experience gained in a range of therapeutic areas with a focus on orphan diseases. Previously Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010 to 2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. Ms. Holles is a member of the Board of Directors for Rubius Therapeutics, Inc. She holds an M.A. in Molecular, Cellular, and Developmental Biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow, and an A.B. in Human Biology from Stanford University.


Elena Ridloff is Executive Vice President, Chief Financial Officer at ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. Ms. Ridloff joined ACADIA in April 2018 as Senior Vice President, Investor Relations from Alexion Pharmaceuticals, where she was Vice President, Investor Relations and served as a member of the Operating Committee. Prior to Alexion, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry. She was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors. Ms. Ridloff earned her B.A. in History and Sociology of Science from the University of Pennsylvania. She is also a CFA® charterholder.

 

Pricing Information*

  • Members: Free
  • Non-Members/Free Unlimited Guest Members*:Free 
  • Optional Donation: $10

Click here to purchase a WIB membership.

 

Note: Zoom meeting link will be sent along with confirmation email, after registration has been completed.

The meeting starts at 9:30 a.m. PT/12:30 p.m. ET

Join Zoom Meeting
https://us02web.zoom.us/j/89685800180

Meeting ID: 896 8580 0180
One tap mobile
+13017158592,,89685800180# US (Germantown)
+13126266799,,89685800180# US (Chicago)

Dial by your location
        +1 301 715 8592 US (Germantown)
        +1 312 626 6799 US (Chicago)
        +1 646 558 8656 US (New York)
        +1 346 248 7799 US (Houston)
        +1 669 900 9128 US (San Jose)
        +1 253 215 8782 US (Tacoma)
Meeting ID: 896 8580 0180
Find your local number: https://us02web.zoom.us/u/k2OFZY70x



Event Capacity

1000

 

Thank you to our sponsor:

 

Thank you to our EWIB National Sponsors:


Elite




Signature

 

Individual